Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: Abbott laboratories | Vintage Vibes

Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Despite Abbott Laboratories' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Stocks Settle Lower as Chipmakers and AI Stocks Slump

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.51%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.62%. September E-mini S&P futures (ESU26 ) fell -0.50%, and September E-mini Nasdaq futures...

Barchart

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Chip Selloff Drags Nasdaq 100, Gold Sinks Below $4,000: Stock Market Today

Another sharp selloff in semiconductors dragged the Nasdaq 100 down more than 1% by midday Thursday, extending a negative week for tech.

Benzinga

Stocks Mixed as Weakness in Chipmakers Weighs

The S&P 500 Index ($SPX ) (SPY ) today is down -0.14%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.96%. September E-mini S&P futures (ESU26 ) are down -0.18%, and September E-mini Nasdaq futures...

Barchart

Abbott Labs shares jump 12% as Q2 sales rise, profit outlook raised

Abbott Laboratories shares surged 12% after the healthcare company reported strong second-quarter sales, raised its full-year earnings outlook and reaffirmed revenue growth guidance. Progress across its medical devices and diagnostics pipeline further boosted investor confidence in future growth.

The Economic Times

Stocks Pressured by a Renewed Selloff in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is down -0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.28%. September E-mini S&P futures (ESU26 ) are down -0.40%, and September E-mini Nasdaq futures...

Barchart

Read news from The Economist, FT, and more,
with one subscription

Abbott Laboratories Federal Formula Safety Probe Quietly Shelved Following Massive Cash Injection To Donald Trump Fund

The US Justice Department has ended its criminal investigation into Abbott Laboratories' contaminated baby formula plant, opting for civil penalties instead, amid scrutiny over political donations.

International Business Times UK

DOJ Dropped Secret Criminal Charges Against Baby Formula Giant Abbott Despite Claims Contaminated Milk 'Sickened And Killed' Infants

The Justice Department has closed its criminal investigation into Abbott Laboratories, opting for civil penalties over charges related to the 2022 baby formula contamination and shortage.

International Business Times UK

Abbott Laboratories' Q2 2026 Earnings: What to Expect

Abbott Laboratories is scheduled to report its second-quarter results in July, and analysts expect a single-digit earnings rise.

Barchart

Is Abbott Laboratories Stock Underperforming the Dow?

Abbott Laboratories has trailed the Dow Jones Industrial Average over the past year, but analysts remain highly optimistic about the company's long-term growth prospects.

Barchart

3 Ultra-Reliable Dividend Kings Trading at Bargain-Basement Prices

These beaten-down Dividend Kings, trading near their 2026 lows, offer income, rebound potential, and Wall Street-backed upside for patient investors.

Barchart

Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity

While ABT stock appears poised to reach the year’s halfway mark in ignominy, the options market is quietly signaling a possible recovery.

Barchart

3 Dividend Aristocrats Under $100 to Buy and Hold Forever

These three Dividend Aristocrats under $100 offer steady payouts, reasonable payout ratios, and analyst-backed upside potential.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell

See the recent insider activity surrounding Okta, Micron Technology, and Abbott Laboratories, and what these moves signal to investors.

MarketBeat

Abbott Stock Crash: Rebound Could Be Coming Fast

Abbott Laboratories' stock price sell-off is overextended in mid-April, creating an opportunity that income investors will not want to miss.

Barchart

Stocks Edge Higher as Chipmakers Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.43%. June E-mini S&P futures (ESM26 ) are up +0.26%, and June E-mini Nasdaq futures...

MarketBeat

A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

Barchart

Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows

Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We rate three that could be.

Barchart

This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound?

Barchart

3 High Dividend Growth Kings for Generations of Income That Are Still Rated ‘Buy’

These 3 Dividend Kings combine steady businesses, rising dividends, and solid upside potential for long-term income investors.

Barchart

Do Wall Street Analysts Like Abbott Laboratories Stock?

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?

Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.

MarketBeat

Is Abbott’s January Pullback a Good Time to Buy?

Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its business and driving cash flow.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.